Impax Board of Directors Appoints G. Frederick Wilkinson President and CEO

Impax Laboratories, Inc.(NASDAQ: IPXL) today announced that its Board of Directors has appointed G.Frederick Wilkinson as Impax's President and Chief Executive Officer effectiveApril 29, 2014. Mr. Wilkinson, who previously served as President, ActavisGlobal Research and Development at Actavis plc succeeds Larry Hsu, Ph.D. whois retiring."A long-time industry leader, Fred's extensive experience in managing generic,brand, R&D, and regulatory and compliance activities, together with his trackrecord in driving change, delivering growth, advancing pipeline products anddriving innovation, make him the perfect candidate for this role," said RobertL. Burr, Chairman of Impax Laboratories, Inc. "I have every confidence thatFred's vision and passion will translate into remarkable success for Impax.The Board would like to thank Dr. Hsu for his incredible dedication andcommitment over the last 18 years and for positioning the Company for its nextphase of growth."Mr. Wilkinson said, "I am grateful to Dr. Hsu and the Board for the privilegeto lead the future direction of the Company and reinforce a quality-firstculture. This is a great company, with a strong balance sheet, experiencedbusiness team and multiple product opportunities. I look forward to buildingon Impax's success." Mr. Wilkinson, 57, joined Watson Pharmaceuticals Inc. (now Actavis) asExecutive Vice President, Global Brands in September 2009. Prior to joiningWatson, he was President and Chief Operating Officer of DuramedPharmaceuticals, Inc., the proprietary products subsidiary of BarrPharmaceuticals Inc. from 2006 to 2009. Prior to joining DuramedPharmaceuticals, Inc., he was President and Chief Executive Officer ofColumbia Laboratories, Inc. from 2001 to 2006. From 1996 to 2001, Mr.Wilkinson was Senior Vice President and Chief Operating Officer of Watson.Prior to joining Watson, he spent 16 years at Sandoz in numerous seniormanagement positions of increasing responsibility. Mr. Wilkinson received aM.B.A. from Capital University in 1984 and a B.S. in Pharmacy from OhioNorthern University in 1979.Impax Laboratories will release its first quarter 2014 financial results afterthe close of the U.S. financial markets on May 1, 2014. Mr. Wilkinson willparticipate in the conference call with the investment community on May 1 at4:30 p.m., Eastern Time.Today's announcement concludes a transition process that began in 2013 whenDr. Hsu first announced his decision to retire. Dr. Hsu will continue to serveon the Impax Board.About Impax Laboratories, Inc.Impax Laboratories, Inc. (Impax) is a technology based specialtypharmaceutical company applying its formulation expertise and drug deliverytechnology to the development of controlled-release and specialty generics inaddition to the development of central nervous system disorder brandedproducts. Impax markets its generic products through its GlobalPharmaceuticals division and markets its branded products through the ImpaxPharmaceuticals division. Additionally, where strategically appropriate, Impaxdevelops marketing partnerships to fully leverage its technology platform andpursues partnership opportunities that offer alternative dosage formtechnologies, such as injectables, nasal sprays, inhalers, patches, creams andointments. For more information, please visit the Company's Web site at:www.impaxlabs.com.